Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of Berzosertib in Advanced Solid Tumors
NCT05246111Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of berzosertib in solid tumor (2 arms), sponsored by Merck KGaA. Primary endpoints: Percent Urinary Recovery of Total Radioactivity, Percent Fecal Recovery of Total Radioactivity and 8 more. Started Feb 2022; status: completed.
02
Drugs
berzosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05246111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05246111.